These findings indicate that inhibition of the CD47-SIRPα antiphagocytic axis and activation of prophagocytic signaling with rituximab have an enhanced antitumor effect in DLBCL cell lines compared with rituximab alone. This evidence concerns the gene SIRPA and diffuse large B-cell lymphoma.